CAS 670220-88-9 appears in our catalog under these names: Crenolanib, 95%, Crenolanib, Crenolanib/ 98.4% (existing batch purity), Crenolanib (CP–868596), Crenolanib 98%. Offered by: Combi-blocks, Chemat Brand, TRC, TargetMol, GLPBio. Available pack sizes: 100mg, on request, 1g, 2mg, 5mg, 10mg, 25mg, 50mg.
Crenolanib is a member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a 8-(4-aminopiperidin-1-yl)quinolin-2-yl group at position 1 and by a (3-methyloxetan-3-yl)methoxy group at position 5. It is an inhibitor of type III tyrosine kinases, PDGFRalpha/beta and FLT3 (IC50 of 11, 3.2, and 4 nM). Currently under clinical development for the treatment of acute myeloid leukemia. It has a role as an antineoplastic agent, an angiogenesis inhibitor, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an apoptosis inducer. It is a member of benzimidazoles, a member of quinolines, an aromatic ether, a member of oxetanes, an aminopiperidine and a tertiary amino compound.
Source: ChEBI
| Molecular formula | C26H29N5O2 |
|---|---|
| Molecular weight | 443.5 g/mol |
| IUPAC name | 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine |
| InChIKey | DYNHJHQFHQTFTP-UHFFFAOYSA-N |
| SMILES | CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4 |
Computed by PubChem (NCBI)